Annatto-extracted tocotrienols improve glucose homeostasis and bone properties in high-fat diet-induced type 2 diabetic mice by decreasing the inflammatory response

Chwan-Li Shen1,4,6, Gurvinder Kaur2,6, Desiree Wanders3, Shaligram Sharma2,3, Michael D. Tomison1, Latha Ramalingam4,6, Eunhee Chung5, Naima Moustaid-Moussa4,6, Huanbiao Mo4 & Jannette M. Dufour2,6

Diabetes is a risk factor for osteoporosis. Annatto-extracted tocotrienols (TT) have proven benefits in preserving bone matrix. Here, we evaluated the effects of dietary TT on glucose homeostasis, bone properties, and liver pro-inflammatory mRNA expression in high-fat diet (HFD)-induced type 2 diabetic (T2DM) mice. 58 male C57BL/6 J mice were divided into 5 groups: low-fat diet (LFD), HFD, HFD + 400 mgTT/kg diet (T400), HFD + 1600 mgTT/kg diet (T1600), and HFD + 200 mg metformin/kg (Met) for 14 weeks. Relative to the HFD group, both TT-supplemented groups (1) improved glucose homeostasis by lowering the area under the curve for both glucose tolerance and insulin tolerance tests, (2) increased serum procollagen I intact N-terminal propeptide (bone formation) level, trabecular bone volume/total volume, trabecular number, connectivity density, and cortical thickness, (3) decreased collagen type 1 cross-linked C-telopeptide (bone resorption) levels, trabecular separation, and structure model index, and (4) suppressed liver mRNA levels of inflammation markers including IL-2, IL-23, IFN-γ, MCP-1, TNF-α, ITGAX and F4/80. There were no differences in glucose homeostasis and liver mRNA expression among T400, T1600, and Met. The order of osteo-protective effects was LFD ≥ T1600 ≥ T400 = Met > HFD. Collectively, these data suggest that TT exerts osteo-protective effects in T2DM mice by regulating glucose homeostasis and suppressing inflammation.

Diabetes mellitus (DM) is a chronic metabolic disorder that affects more than 30.3 million people in the United States; an additional 84.1 million individuals have been diagnosed with prediabetes1. DM with long-term hyperglycemia may have a direct, adverse impact on bone and the bone marrow microenvironment including (i) advanced glycation end products of bone matrix proteins2, (ii) chronic inflammation and abnormal cytokine and adipokine production, resulting in detrimental effects on bone cells, (iii) impaired neuromuscular/skeletal interactions3,4, and (iv) excessive production of reactive oxygen species5. Mediated by the alterations of these enzymatic and non-enzymatic events, DM induces crosslinking negative effects including significant bone loss, poor bone quality and impaired biomechanical properties in spontaneously diabetic WBN/Kob rats6. Animal studies in streptozotocin (STZ)-induced DM rats have confirmed that a relationship exists between type 1 DM and poor bone quality7. In humans, Miyaka et al. recently showed the association of reduced bone mineral density and
several vertebral fractures with increased mortality in people with type 2 DM (T2DM)\(^8\). A recent meta-analysis confirmed that there was an increased prevalence of low bone mass-related fractures in people with T2DM compared to those without T2DM\(^9\).

T2DM is characterized by peripheral insulin resistance with a variable degree of hyperglycemia and impaired insulin secretion after metabolic challenge by glucose\(^10\). In T2DM, chronic oxidative stress and inflammation, resulting from enhanced exposure to oxidants, can lead to insulin resistance and impaired insulin signaling and glucose transport in skeletal muscle\(^11\). Oxidative stress and chronic inflammation have detrimental effects on skeletal muscle, pancreatic beta cells, and bone\(^2,12,13\), causing imbalance in bone metabolism and bone loss\(^2,12–14\).

The use of dietary supplements, botanicals, and nutraceuticals has become an alternative approach to prevent and mitigate the complications of hyperglycemia in people with T2DM, including alleviating inflammation and maintaining the oxidant-antioxidant balance\(^15\). Vitamin E is a collective term for tocopherols and tocotrienols (TT)\(^16\). Both tocopherols and TT exist in 4 different methyl substitutions in nature: alpha (\(\alpha\)), beta (\(\beta\)), gamma (\(\gamma\)), and delta (\(\delta\)) consisting of a mixture of varying compositions\(^16\). Most plant species contain tocopherols, whereas TT can only be found in certain plants such as annatto, palm, grains, and nuts\(^17\). Preclinical studies have shown the effect of a mixture of TT on glucose homeostasis in STZ-treated type 1 DM animals through down-regulation of transforming growth factor-\(\beta\)\(^18\) or suppression of oxidative stress\(^19\). Vafa et al. further reported that supplementation of TT-enriched canola oil reduced fasting blood sugar levels and lipid oxidation, while increasing total antioxidant capacity in T2DM patients\(^20\). With regard to bone aspect, several animal studies using \(\delta\)-TT\(^21\), \(\gamma\)-TT\(^22\), palm oil-extracted TT\(^23\), and annatto-extracted TT\(^24\) in sex hormone-deficient animal models all showed the osteo-protective effects of TT in terms of bone matrix and microstructure. However, no study has yet evaluated the beneficial effects of TT on bone properties in animals with T2DM.

With its strong anti-oxidative/anti-inflammatory properties, annatto-extracted TT, consisting of 90% \(\delta\)-TT and 10% \(\gamma\)-TT, would be a good candidate to evaluate TT’s effects on T2DM-related complications, such as hyperglycemia and bone deterioration. We previously reported that \(\delta\)-TT inhibited adipogenesis in 3T3-F442A preadipocytes\(^25\) and increased fatty acid oxidation, reduced adipocyte hypertrophy, and suppressed inflammation in both liver and adipose tissue\(^26\). In this paper, we focused on the beneficial effect of annatto-extracted TT on glucose homeostasis and bone health in a high-fat diet (HFD)-induced T2DM model. We hypothesized that annatto-extracted TT has both anti-diabetic and anti-osteoporotic properties in HFD-induced T2DM animals through suppression of inflammation.

### Results

#### Body weight, feed intake, and water consumption.

Figure 1 presents the mean body weight for different treatment groups. At baseline, there was no significant difference in body weight among all groups. Throughout the study period, body weight significantly increased in all animals regardless of treatment. From 8 weeks to the end of study, the body weight significantly increased in all HFD-fed treatment groups relative to the low-fat diet (LFD) group. At both 12 and 14 weeks, there was no significant difference in body weight among the HFD, T400, and T1600 groups. At the end of the 14-week study, the statistical results showed the order of body weight as follows: T1600 group = HFD group > T400 group > metformin (Met) group > LFD group (\(p < 0.001\)). Throughout the study, the average food intake by weight and water consumption were similar among all groups (both \(p > 0.05\)).

#### Glucose homeostasis and morphological analysis of the pancreas.

The effects of TT supplementation on glucose homeostasis (Table 1) were assessed by glucose tolerance test (GTT) and insulin tolerance test (ITT), serum and pancreatic insulin levels\(^37\), and pancreatic histology (Fig. 2). Relative to the LFD group,
between the HFD group and the Met group. Structures in obese mice, as shown by no significant difference in any of the bone microstructure parameters prevented the obesity-induced loss of femoral cortical thickness (Ct.Th) and restored it to the level of LFD group and total area (T.Ar) was observed between any treatment groups. TT supplementation (both T400 and T1600) resulted in no difference between the T1600 and the LFD group.

In Tb.Sp and SMI at both LV-4 and femur. The osteo-protective impacts of T1600 treatment on these trabecular structures was reversed in T400, T1600, and Met groups. There was no significant difference in CTX among the LFD, T400, and T1600 groups. Furthermore, the Met group had the lowest serum P1NP concentrations among all treatment groups. The HFD group had an increased serum CTX than the LFD group, an effect that was reversed in T400, T1600, and Met groups. There was no significant difference in CTX among the LFD, T400, T1600, and Met groups.


table 1. Effect of annatto-extracted tocotrienol supplementation on glucose homeostasis. * Values are mean ± SEM, n ≥ 6. Within the same column, values not sharing a common letter are statistically different (p < 0.05). LFD, low-fat diet; HFD, high-fat diet; T400, HFD + TT at 400 mg TT/kg diet; TT1600, HFD + TT at 1600 mg TT/kg diet; Met, HFD + metformin at 200 mg metformin/kg diet; AUC, area under the curve; GTT, intra-peritoneal glucose tolerance test; ITT, intra-peritoneal insulin tolerance test.

| Groups | Time (min) | 0 | 15 | 30 | 60 | 120 | AUC |
|--------|------------|---|----|----|----|-----|-----|
|        |            |   |    |    |    |     |     |
|        | LFD        | 150.4 ± 8.8 | 408.9 ± 23.8 | 409.4 ± 26.5 | 227.5 ± 12.9 | 160.6 ± 8.9 | 31541.6 ± 1455.7 |
|        | HFD        | 186.3 ± 10.6 | 506.2 ± 24.5 | 542.0 ± 16.9 | 512.3 ± 37.8 | 369.3 ± 22.6 | 55486.5 ± 2522.1 |
|        | T400       | 163.3 ± 7.5 | 478.9 ± 24.0 | 512.1 ± 19.1 | 408.8 ± 30.0 | 285.1 ± 20.5 | 46889.0 ± 1710.9 |
|        | T1600      | 155.5 ± 9.1 | 473.7 ± 22.9 | 517.5 ± 24.9 | 428.0 ± 12.2 | 228.8 ± 18.9 | 46041.5 ± 1626.2 |
|        | Met        | 148.5 ± 5.5 | 485.2 ± 29.8 | 547.2 ± 15.3 | 423.5 ± 16.2 | 257.3 ± 12.6 | 47479.5 ± 1154.2 |

Microarchitectural properties of LV-4 and femur. Table 2 exhibits the effects of TT supplementation on trabecular microarchitecture at lumbar vertebrae-4 (LV-4) and the femur. As expected, the HFD adversely affected 3-dimensional bone microstructure. Compared to the LFD group, HFD significantly decreased LV-4 and femoral trabecular bone volume/total volume (BV/TV), trabecular number (Tb.N), and connectivity density (Conn.Dn), increased trabecular separation (Tb.Sp) and structure model index (SMI), and had no effect on trabecular thickness (Tb.Th). TT supplementation (both T400 and T1600) mitigated the HFD-induced deterioration of trabecular bone microstructure as shown by increases in BV/TV, Tb.N, and Conn.Dn and decreases in Tb.Sp and SMI at both LV-4 and femur. The osteo-protective impacts of T1600 treatment on these trabecular bone microstructures (e.g., LV-4 SMI and all distal femur trabecular bone parameters) of obese mice are greater than those of T400 treatment, resulting in no difference between the T1600 and the LFD group.

Effects on liver mRNA expression. Relative to the LFD group, the HFD group significantly upregulated liver mRNA expression of pro-inflammatory cytokines including interleukin (IL)-2, IL-23, interferon (IFN)-γ, monocyte chemoattractant protein (MCP)-1, and monocyte/macrophage markers such as ITGAX, and F4/80.
The levels of hepatic mRNA of the pro-inflammatory cytokines and monocyte/macrophage markers in the T400, T1600 and Met groups were significantly lower than those of the HFD group, but not different from those of the LFD group.

Discussion
In this study, we employed a HFD-induced obese T2DM rodent model to examine the effects of TT supplementation on glucose homeostasis and bone properties and underlying molecular mechanisms in male mice. To the best of our knowledge, this is the first in vivo study to demonstrate the efficacy of annatto-extracted TT on osteo-protection in an obese T2DM model, possibly via the suppression of inflammation and regulation of glucose homeostasis.

Consistent with previous studies, HFD feeding produced a detrimental effect on bone matrix and bone microarchitecture indicated by lowered trabecular volume fraction, number, and Conn. Dn, and increased trabecular separation and SMI in LV-4 and femur (Table 2). Importantly, TT conserved bone matrix and protected bone microstructure from deterioration in HFD male mice, which supports our hypothesis that TT increased BV/TV through restoring bone microstructure (an increase in Tb.N and SMI as well as a decrease in Tb.Sp and Conn. Dn). In addition, as shown in Fig. 3, TT supplementation in the diet mitigated bone deterioration in HFD-fed...
male rats, palm oil-extracted TT to ovariectomized rats, and annatto-TT to orchidectomized rats. The ability of TT to improve bone microstructure and function and number, gene expression, and maturation is in agreement with previous studies in which TT-rich fractions from palm or rice bran oils were shown to improve insulin resistance and improve bone health.

One likely mechanism driving osteoporosis in the T2DM population is impaired glucose homeostasis. For example, hyperglycemia can cause an increase in differentiation of bone marrow mesenchymal cells into adipocytes, which in turn could increase adipogenesis and attenuate osteogenesis as a result of suppression of osteoblast function and number, gene expression, and maturation. While hyperglycemia, elevated serum triglycerides and insulin resistance were observed in the HFD group, supplementation with TT for 14 weeks significantly improved bone microstructure properties of LV-4 and femur. A values are mean ± SEM, n = 10. Within the same row, values not sharing a common letter are statistically different (p < 0.05). B.Pm, bone perimeter; BV/TV, bone volume/total volume; B.Ar, cross-sectional bone area; Conn.Dn, connectivity density; Ct.Th, cortical thickness; HFD, high-fat diet; LFD, low-fat diet; LV-4, lumbar vertebrae-4; Met, HFD + metformin at 200 mg/kg diet; T400, HFD + TT at 400 mg/kg diet; TT1600, HFD + TT at 1600 mg/kg diet; T.Ar, cross-sectional total area; Tb.N, trabecular number; Tb.Pf, trabecular bone pattern factor; Tb.Sp, trabecular separation; Tb.Th, trabecular thickness; SMI, structure model index.

Table 2. Effect of annatto-extracted tocotrienol supplementation on bone microstructure properties of LV-4 and femur. Values are mean ± SEM, n = 10. Within the same row, values not sharing a common letter are statistically different (p < 0.05). IL-2, interferon-γ; IL-10, interleukin; ITGAX, integrin subunit alpha x; MCP-1, monocyte chemoattractant protein-1.

Table 3. Effect of annatto-extracted tocotrienol supplementation on liver mRNA expression. Data are mean ± SEM. Within the same row, values not sharing a common letter are statistically different (p < 0.05). IFN-γ, interferon-γ; IL, interleukin; ITGAX, integrin subunit alpha x; MCP-1, monocyte chemoattractant protein-1.
significantly improved glycemic status in diabetic rats. In addition, our results also are in the agreement with Wong’s finding that β-TT improved glucose tolerance and insulin sensitivity in diet-induced obese rats. We noted that there was no increase in serum insulin concentrations in HFD-fed mice with insulin resistance. The lack of such an increase indicates the pancreatic β cells were not responding by increasing insulin secretion, even though the animals may remain insulin resistant. The mechanisms underlying the uncoupling of insulin resistance and elevated plasma insulin warrants further investigation.

Intriguingly, in our study, annatto-extracted TT was as effective as metformin in lowering fasting blood glucose levels and improving glucose tolerance. Analysis of the pancreas by immunostaining revealed no gross morphological changes in the alpha (as demonstrated by glucagon staining) or beta (as demonstrated by insulin staining) islet cells between any of the treatment (the HFD, T400, T1600 and Met) groups and the LFD group (Fig. 2). Consistently, TUNEL analysis of the pancreas from LFD and HFD groups showed no differences in the number of apoptotic cells. Hyperinsulinemia was not observed in any of the mice at the time of sample collection. The lack of elevated serum and pancreatic insulin levels in the fasting HFD mice along with no gross morphological changes in the islets, despite an increase in blood glucose levels, suggests possible beta cell dysfunction rather than beta cell loss as the islets should respond to elevated blood glucose by increasing insulin production and secretion. Prolonged exposure to hyperglycemia and hyperlipidemia can result in beta cell glucotoxicity and lipotoxicity. Confirmation of beta cell dysfunction will require further analysis in future studies.

Metformin, a commonly used drug for the initial treatment of patients with T2DM (American Diabetes Association), was shown to benefit bone metabolism. Metformin increases trabecular bone formation through activation of AMPK signaling, a major intracellular pathway that senses energy starvation, in osteoblastic cells. Metformin also promotes osteoblast differentiation and inhibits differentiation of stem cells into adipocytes through an inhibition of PPARδ, a nuclear receptor that regulates lipid and glucose metabolism. Li et al. reported that metformin re-balances catabolism and nitrogen disposal and improves bone homeostasis in animal models of hyperglycemia. Moreover, male diabetic patients taking metformin had a significant reduction of serum bone resorption. In this study, we compared the impact of metformin treatment and annatto-TT supplementation on glucose homeostasis, bone turnover biomarkers, and bone microstructure. It was observed that annatto-TT has an equal (the T400 group = the Met group) or even more favorable impact (the T1600 group > the Met group) on ITT AUC, serum P1NP, Tb.Th, Conn. Dn, Tb.Sp, SMI, and Ct.Th, suggesting TT-supplementation may be an alternative to Met for controlling hyperglycemia and providing bone benefits simultaneously. Such findings corroborate our previous finding that anti-diabetic supplementation, Yunzhi with anti-oxidant and anti-inflammatory characteristics, improved bone properties in diabetic rats, in part, by improvement in hyperglycemic control in STZ-induced DM animals.

Inflammation may be the most important mechanism linking obesity to the development of T2DM. Emerging evidence has suggested that in the development of obesity, greater adipose tissue mass directly contributes to systemic inflammation and chronic oxidative stress that are detrimental to bone. T2DM-related systemic chronic inflammation can elevate bone inflammatory cells and mediators, leading to an inhibition of osteoblast markers and bone microstructure. It was observed that annatto-TT supplementation had a significantly improved glycemic status in diabetic rats. In our study, we confirmed that annatto-extracted TT lowered fasting blood glucose levels and improved glucose tolerance. Analysis of the pancreas by immunostaining revealed no gross morphological changes in the alpha (as demonstrated by glucagon staining) or beta (as demonstrated by insulin staining) islet cells between any of the treatment (the HFD, T400, T1600 and Met) groups and the LFD group (Fig. 2). Consistently, TUNEL analysis of the pancreas from LFD and HFD groups showed no differences in the number of apoptotic cells. Hyperinsulinemia was not observed in any of the mice at the time of sample collection. The lack of elevated serum and pancreatic insulin levels in the fasting HFD mice along with no gross morphological changes in the islets, despite an increase in blood glucose levels, suggests possible beta cell dysfunction rather than beta cell loss as the islets should respond to elevated blood glucose by increasing insulin production and secretion. Prolonged exposure to hyperglycemia and hyperlipidemia can result in beta cell glucotoxicity and lipotoxicity. Confirmation of beta cell dysfunction will require further analysis in future studies.

The increased expression of Igbz (CD11c) and Adgrel (F4/80) in the livers of HFD-fed mice indicates the increased presence of immune cells, likely inflammatory (M1) macrophages. The HFD-fed mice also had increased inflammatory cytokine expression in the liver, and TT normalized the expression of these inflammatory cytokines to levels comparable to LFD-fed mice (Table 2). These data indicate that TT prevents HFD-induced hepatic inflammation, despite having no effect on body weight. Our previous work found that treating HFD-fed mice with TT decreased adipose tissue inflammation, adipocyte size, and macrophage infiltration in the adipose tissue. Additionally, we reported decreased hepatic steatosis and serum triglyceride levels and reduced macrophage infiltration in the liver. Moreover, 4 weeks of γ-TT treatment decreases HFD-induced systemic and adipose tissue inflammation. It is well known that adipose tissue inflammation is strongly linked to hepatic inflammation. Thus, it is possible that the anti-inflammatory effects of TT in adipose tissue lead to secondary reductions in hepatic inflammation, although direct anti-inflammatory effects in hepatocytes and in the heart were previously reported.

The 400 and 1600 mg/kg diet doses of TT for mice are equivalent to daily doses of 160 mg and 640 mg, respectively, for a 70-kg human adult, based on body surface areas of mice and humans. Since TT can only be found in certain plants, e.g., annatto, palm, grains, nuts, and rubber, such doses in humans are likely obtainable through supplements rather than diet.

We recently reported a mechanism of bone protection by TT through the enhancement of antioxidant capacities and the suppression of oxidative stress and inflammation.

In the present investigation, we corroborated the ability of annatto-extracted TT, a generally recognized as safe (GRAS) dietary supplement, to improve glucose homeostasis and mitigate the deterioration of bone microarchitecture in obese male mice. Our data demonstrate that supplementation of TT in a HFD has anti-diabetic effects by improving glucose intolerance and insulin intolerance, and also has osteo-protective effects by conserving...
bone matrix and microarchitecture in HFD-induced obese mice with hyperglycemia and insulin resistance. These osteoprotective effects may be mediated in part through favored bone turnover markers as well as bone remodeling along with modulated cancellous and endocortical bone compartments, resulting in a larger net bone matrix.

The primary goal of this study was to determine whether TT improves glucose homeostasis and mitigates bone deterioration in obesity/diabetes through suppression of inflammation. Therefore, the most relevant model of human obesity/diabetes is the high-fat diet-induced obese mice with elevated inflammation, insulin resistance, and glucose tolerance. However, it would be interesting to also know the benefits of TT in lean or low fat fed models without chronic inflammation or altered glucose metabolism, and we hope to conduct such studies in the future.

We noted that histological data showing decreased inflammation in bone and liver, and changes in osteoclasts/osteoblasts would have further supported the mechanisms of action. We previously reported that both T400 and T1600 reduce inflammation in the liver histologically28. In the present study, as an alternative to histology, we demonstrated that both T400 and T1600 groups mitigated HFD-induced bone microstructure deterioration (Table 2). In future studies, we should include such histological findings to support the mechanisms of action due to TT. Furthermore, it is also worthy to investigate the effect of TT on functional parameters to show if the increased risk of fracture in osteoporotic bones can be alleviated by TT treatment.

In summary, in the present study, annatto-extracted TT was assessed as an alternative dietary supplement for bone health in obese mice with glucose intolerance and insulin intolerance. Our data show that annatto-extracted TT has anti-diabetic and bone-protective effects in terms of glucose homeostasis, bone turnover biomarkers, bone volume, and bone microarchitecture in obese mice through, in part, a suppression of liver inflammation. The current animal study represents a critical step towards understanding the impact of annatto-extracted TT on bone health in obese T2DM patients. Given the millions of individuals afflicted with diabetes or prediabetes who are also at risk for developing osteoporosis, the results of this study could have a significant impact on future treatment strategies. Future studies based on the current animal study are warranted to address the differences between obese T2DM male mice and obese T2DM patients and the translational value of annatto-extracted TT in glucose homeostasis management and bone health.

Materials and Methods

Animals and treatments. Fifty-eight male C57BL/6J mice (5-week-old, Jackson Laboratory, Bar Harbor, ME, USA) were fed chow diet and distilled water ad libitum for 5 days. After acclimatization, mice were weighed, randomly stratified by weight and assigned to 5 groups: low-fat diet group (LFD, 5% of energy from fat), HFD group (58% of energy from fat), HFD + 400 mg TT/kg diet (T400), HFD + 1600 mg TT/kg diet (T1600), and HFD + 200 mg metformin/kg diet (Met, used as a positive control treatment for T2DM) for 14 weeks. Animals had free access to water and diet during the study period. TT (gift from American River Nutrition, Inc., Hadley, MA) was extracted from annatto oil and 70% pure, containing 90% δ-TT and 10% γ-TT. TT was premixed with tocopherol-stripped soybean oil (Dytes Inc., Bethlehem, PA) before being added to HFD. Previous animal studies showed the osteoprotective impacts of delta-tocotrienol at 60 mg/kg body weight in rats21,24. Our T400 and T1600 mg/kg diet in mice corresponds to 28 mg/kg body weight and 112 mg/kg body weight in rats, respectively, which is comparable with the previous published works21,24.

Mice were housed in cages of three and maintained at a controlled temperature of 21 ± 2 °C with a 12 h light-dark cycle. Each treatment group had 4 cages of mice. All animals were observed daily for clinical signs of disease. Body weight, food intake, and water consumption were recorded weekly. All conditions and handling of the animals were approved by the Texas Tech University Health Sciences Center Institutional Animal Care and Use Committee. All experiments were performed in accordance with the relevant guidelines and regulations.

In vivo glucose and insulin tolerance tests. Intraperitoneal GTT was performed after 12 weeks of treatment. Glucose (2 mg/g body weight) was injected intraperitoneally into mice (n > 6 per treatment group) fasted for 4 h. Blood samples for glucose determination were obtained prior to (0 mins) and at 15, 30, 60, and 120 mins following glucose administration. For intraperitoneal ITT, after 12 weeks of treatment, mice (n = 6 per treatment group) were fasted for 4 h prior to intraperitoneal injection of insulin (Humulin, Abbott, Chicago, IL) at 1 U/kg body weight. Blood glucose was measured prior to (0 mins) and at 15, 30, 60, and 120 mins following insulin injection. The AUC was calculated by trapezoidal method.

Sample collection. At the end of the experiment, animals were fasted for 4-hours and blood was collected from mice anesthetized with isoflurane. Femur and lumbar vertebrae-4 (LV-4) were harvested and cleaned of soft tissue. Glucose (2 mg/g body weight) was injected intraperitoneally into mice (n > 6 per treatment group) fasted for 4 h. Blood samples for glucose determination were obtained prior to (0 mins) and at 15, 30, 60, and 120 mins following glucose administration. For intraperitoneal ITT, after 12 weeks of treatment, mice (n = 6 per treatment group) were fasted for 4 h prior to intraperitoneal injection of insulin (Humulin, Abbott, Chicago, IL) at 1 U/kg body weight. Blood glucose was measured prior to (0 mins) and at 15, 30, 60, and 120 mins following insulin injection. The AUC was calculated by trapezoidal method.

Analysis of pancreatic tissue. At the end of the experiment, pancreases (n = 4 per treatment group) were fixed in Z-fix and paraffin embedded for histological assessment. Tissue sections were immunostained for insulin (BioGenex, Ferman, CA) and mouse anti-glucagon (diluted 1:5000; Sigma). Biotinylated secondary antibodies and avidin–biotin–enzyme complexes were purchased from Vector Laboratories (Burlingame, CA). Diaminobenzidine was used as a chromogen (BioGenex, Fermont, CA). All sections were counterstained with hematoxylin. Apoptosis was determined using the DeadEnd™ Fluorometric TUNEL assay (Apoptosis Detection System; Promega Corporation, Madison, WI) according to the manufacturer’s instructions. Negative controls included sections incubated without the TdT enzyme. For quantification, the total number of apoptotic cells per tissue section was counted and normalized to the total tissue area.
**Serum biomarkers analyses.** The concentrations of P1NP and CTX were determined in serum using the respective kits (Immunodiagnostic System Ltd, Scottsdale, AZ, USA). Intra-assay and inter-assay coefficients of variance were 5.0% and 8.0% for P1NP as well as 5.6% and 10.5% for CTX, respectively.

**Bone microarchitecture measurement with μ-CT.** The LV-4 and right femur were scanned using micro-computed tomography (μ-CT) (Model: Scanco μCT 40; SCANCO Medical AG, Switzerland) following the procedures of Cao et al. and the recommended guidelines for μ-CT scanning. Bone nomenclature was based on Parfitt et al. Trabecular parameters in both LV-4 and femur included BV/TV, Tb.N, Tb.Th, Tb.Sp, Conn.Dn, and SMI. Cortical parameters in femur included B.Ar, T.Ar, and Ct.Th.

**Measurement of mRNA expression in liver.** RNA was extracted from liver samples using an RNeasy mini kit (QIAGEN, Valencia, CA). On-column DNA digestion was performed using QIAGEN's RNase-free DNase set. RNA was quantified using the Nanodrop ND 1000 Spectrophotometer. 2 μg RNA was reverse transcribed to produce cDNA. Gene expression was measured by real-time PCR (Applied Biosystems, Foster City, CA) by measurement of SYBR Green. mRNA levels were normalized to cyclophilin expression, and were analyzed using the 2−ΔΔCT method. Cyclophilin expression levels were unchanged in response to diet or treatment group. Primer sequences are as follows: *Cc12* (MCP-1) Fwd 5′-GGAGAGACAGCGGTCTGAAG-3′; Rev 5′-CACAGCGACACTGTA-3′; *Emr1* (F4/80) Fwd 5′-TGGCATTACCTGCGGATT-3′; Rev 5′-GACC CGTACAGACATGTA-3′; 112 Fwd 5′-CATGCAGCTGCCATCTCGT-3′; Rev 5′-AATGGGGCTTGAAG TGAGG-3′; 1123 Fwd 5′-CCTGAGCTTACGCCAGAAA-3′; Rev 5′-AAAAAGTACCGCAAGTCT-3′; *Il10* Fwd 5′-GGACGGCTACCAACAACCCAGGTT-3′; Rev 5′-GGGCAATCTCTCCTGCCCACC-3′; *Il17* Fwd 5′-GGAGGTACGTTACGGTAC-3′; Rev 5′-CTCTGAAATCTCTGACGTT-3′; *Ppia* (Cyclophilin) Fwd 5′-CTTCGAGCTTTTGGACAAAG-3′; Rev 5′-AGATGGCCGACCTGTATGTC-3′.

**Statistical analysis.** Results were presented as mean ± standard error of the mean (SEM). For TUNEL quantification, significant differences in means were determined by the unpaired Student’s t-test method. All the other data were tested by one-way analysis of variance (ANOVA) followed by Fisher’s Least Significant Difference (LSD) post hoc test with SigmaStat software, version 12.5 (Systat Software, Inc., San Jose, CA). A significance level of p < 0.05 applies to all statistical tests.

**References**

1. New CDC report: more than 100 million Americans have diabetes or prediabetes. Accessed on May 21, https://www.cdc.gov/media/releases/2017/p0718-diabetes-report.html (2018).

2. Kanazawa, I. Interaction between bone and glucose metabolism. *Endocr J.* 61(11): 1043–1053 Review (2017).

3. Schwartz, A. V. Diabetes mellitus: does it affect bone? *Calcif Tissue Int.* 73, 515–519 (2003).

4. Leidig-bruckner, G. & Ziegler, R. Diabetes mellitus—a risk for osteoporosis? *Exp Clin Endocrinol Diabetes.* 109(Suppl 2), S493–S514 (2001).

5. Sheweita, S. A. & Khoshhal, K. I. Calcium metabolism and oxidative stress in bone fractures: role of antioxidants. *Curr Drug Metab.* 8(5), 519–525 Review (2007).

6. Saito, M., Fuji, K., Mori, Y. & Marumo, K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. *Osteoporosis Int.* 17, 1514–1523 (2006).

7. Erdal, N., Gürgül, S., Yakav, S., Yıldız, A. & Emre, M. Deterioration of bone quality by streptozotocin (STZ)-induced type 2 diabetes mellitus in rats. *Biol Trace Elem Res.* 140(3), 342–353 (2011).

8. Miyake, H., Kanazawa, I. & Sugimoto, T. Association of Bone Mineral Density, Bone Turnover Markers, and Vertebral Fractures with All-Cause Mortality in Type 2 Diabetes Mellitus. *Calcif Tissue Int.* 102(1–3) (2018).

9. Ni, Y. & Fan, D. Diabetes mellitus is a risk factor for low bone mass-related fractures: A meta-analysis of cohort studies. *Medicine (Baltimore)* 96(51), e8811 (2017).

10. Leslie, W. D., Rubin, M. R., Schwartz, A. V. & Kanis, J. A. Type 2 diabetes and bone. *J Bone Miner Res.* 27(11), 2231–2237 (2012).

11. Henriksen, E. J., Diamond-Stanic, M. K. & Marchionne, E. M. Oxidative stress and the etiology of insulin resistance and type 2 diabetes. *Free Radic Biol Med.* 51(5): 993-999 Review (2011).

12. Banfi, G., Iorio, E. L. & Corsi, M. Oxidative stress-free radicals and bone remodeling. *Clin Chem Lab Med.* 46(11), 1550–1555 (2008).

13. Napoli, N. et al. IOF B and Diabetes Working Group. Mechanisms of diabetes mellitus-induced bone fragility. *Nat Rev Endocrinol.* 13(4): 208-219 (2017).

14. Redlich, K. & Smolen, J. S. Inflammatory bone loss: pathogenesis and therapeutic intervention. *Nat Rev Drug Discov.* 11(3), 234–250 (2012).

15. Goithai, S. et al. Natural Phyto-Bioactive Compounds for the Treatment of Type 2 Diabetes: Inflammation as a Target. *Nutrients.* 8(8). pii: E461 Review (2016).

16. Ahsan, H., Ahad, A., Ishq, I. & Siddiqui, W. A. Pharmacological potential of tocotrienols: a review. *Nutr Metab (Lond).* 11(1), 52 (2014).

17. Panfili, G., Fratianni, A. & Iruno, M. Normal phase high-performance liquid chromatography method for the determination of tocopherols and tocotrienols in cereals. *J Agric Food Chem.* 51, 3940–3944 (2003).

18. Siddiqui, S., Ahsan, H., Khan, M. R. & Siddiqui, W. A. Protective effects of tocotrienols against lipid-induced nephropathy in experimental type-2 diabetic rats by modulation in TGF-β expression. *Texitol Appl Pharmacol.* 273(2), 314–324 (2013).

19. Budin, S. B. et al. The effects of palm oil tocotrienol-rich fraction supplementation on biochemical parameters, oxidative stress and the vascular wall of streptozotocin-induced diabetic rats. *Clinics (Sao Paulo).* 64(3), 235–244 (2009).

20. Vafa, M., Haghighat, N., Moslehi, N., Eghtesadi, S. & Heydari, I. Effect of Tocotrienols and Lovastatin combination on osteoblast and osteoclast activity in estrogen-deficient osteoporosis. *Evid Based Complement Alternat Med.* 2012, 960742 (2012).

21. Abdul-Majeed, S., Mohamed, N. & Soelaiman, I. N. Effects of tocotrienol and lovastatin combination on osteoblast and osteoclast activity in estrogen-deficient osteoporosis. *Evid Based Complement Alternat Med.* 2012, 161527 (2012).
24. Chin, K. Y., Abdul-Majeed, S., Fosti, N. F. & Ima-Nirwana, S. Annatto tocotrienol improves indices of bone static histomorphometry in osteoporosis due to testosterone deficiency in rats. *Nutrients*. 6(11), 4974–4983 (2014).
25. Torabi, S., Yeganehjooh, H., Shen, C. L. & Ho, P. Peroxisome proliferator-activated receptor γ down-regulation mediates the inhibitory effect of δ-tocotrienol on the differentiation of murine 3T3-F442A preadipocytes. *Nutr Res*. 36(12), 1345–1356 (2016).
26. Allen, L. et al. Effects of δ-tocotrienol on obesity-related adipocyte hypertrophy, inflammation and hepatic steatosis in high-fat-fed mice. *J Nutr Biochem*. 48, 128–137 (2017).
27. Ha, H., Lee, J. H., Kim, H. N. & Lee, Z. H. Alpha-Tocotrienol inhibits osteoclast bone resorption by suppressing RANKL expression and signaling and bone resorbing activity. *Biochem Biophys Res Commun*. 406, 546–551 (2011).
28. Cao, J. J., Sun, L. & Gao, H. Diet-induced obesity alters bone remodeling leading to decreased femoral trabecular bone mass in mice. *Ann N Y Acad Sci*. 1192, 292–297 (2010).
29. Shuid, A. N., Mehat, Z., Mohamed, N., Muhammad, N. & Soelaiman, I. N. Vitamin E exhibits bone anabolic actions in normal male rats. *J Bone Miner Res*. 28(2), 149–156 (2010).
30. Nizar, A. M., Nazrun, A. S., Norazlina, M., Norliza, M. & Ima-Nirwana, S. Low dose of tocotrienols protects osteoblasts against oxidative stress. *Clin Ter* 162(6), 533–538 (2011).
31. Brooks, R., Kallia, P., Ireland, D. C., Beeton, C. & Rushton, N. Direct inhibition of osteoclast formation and activity by the vitamin E isomer gamma-tocotrienol. *Int J Vitam Nutr Res*. 81(6), 358–367 (2011).
32. Keats, E. & Khan, Z. A. Unique responses of stem cell-derived vascular endothelial and mesenchymal cells to high levels of glucose. *PLoS One*. 7(6), e38752 (2012).
33. Wong, W. Y., Ward, L. C., Fong, C. W., Yap, W. N. & Brown, L. Anti-inflammatory γ- and δ-tocotrienols improve cardiovascular, liver and metabolic function in diet-induced obese rats. *Eur J Nutr* 56(1), 133–150 (2017).
34. Croop, M., Welsh, N., Jonas, J. C., Jorns, A., Lenzen, S. & Eizirik, D. L. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. *Diabetes*. 54(Suppl 2), S97–S107 (2005).
35. Gao, X., Yue, J., Li, X., Jia, Y. & Hu, J. Metformin regulates osteoblast and adipocyte differentiation of rat mesenchymal stem cells. *J Pharm Pharmacol*. 60(12), 1695–1700 (2008).
36. Zinman, B. et al. ADOPT Study Group Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. *J Clin Endocrinol Metab*. 95(1), 134–140 (2010).
37. Li, X., Guo, Y., Yan, W., Snyder, M. P. & Li, X. Metformin Improves Diabetic Bone Health by Re-Balancing Catabolism and Nitrogen Disposal. *PLoS One*. 10(12), e0146152 (2015).
38. Saltiel, A. R. & Olefsky, J. M. Inflammatory mechanisms linking obesity and metabolic disease. *J Clin Invest*. 127(1), 1–4 (2017).
39. Alvehus, M., Burén, I., Sjöström, M., Goedecke, J. & Olsson, T. The human visceral fat depot has a unique inflammatory profile. *Obesity (Silver Spring)*. 18(3), 879–883 (2010).
40. You, T. & Nicklas, B. J. Chronic inflammation: role of adipose tissue and modulation by weight loss. *Curr Diabetes Rev*. 2(1), 29–37 (2006).
41. Grattaglioni, I., Palmieri, V. O., Portincasa, P., Moschetta, A. & Palasciano, G. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. *J Nutr Biochem*. 19(8), 491–504 (2008).
42. Halade, G. V., El Jamali, A., Williams, P. J., Fajardo, R. J. & Fernandes, G. Obesity-mediated inflammatory microenvironment stimulates osteoclastogenesis and bone loss in mice. *Exp Gerontol*. 46(1), 43–52 (2011).
43. Ionova-Martin, S. S. et al. Changes in cortical bone response to high-fat diet from adolescence to adulthood in mice. *Osteoporos Int*. 22(8), 2283–2293 (2011).
44. Xiao, Y. et al. Dyslipidemic high-fat diet affects adversely bone metabolism in mice associated with impaired antioxidant capacity. *Nutrition*. 27(2), 214–220 (2011).
45. Cai, D. et al. Metformin Improves Diabetic Bone Health by Re-Balancing Catabolism and Nitrogen Disposal. *PLoS One*. 10(12), e0146152 (2015).
46. Motyl, K. J. et al. Bone inflammation and altered gene expression with type 1 diabetes early onset. *J Cell Physiol*. 218(3), 575–583 (2009).
47. Cai, D. et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. *Nat Med*. 11, 183–190 (2005).
48. Lackey, D. E. & Olefsky, J. M. Regulation of metabolism by the innate immune system. *Nat Rev Endocrinol*. 12(1), 15–28 (2016).
49. Cao, J. J., Gregoire, B. R. & Shen, C. L. A High-Fat Diet Decreases Bone Mass in Growing Mice with Systemic Chronic Inflammation Induced by Low-Dose, Slow-Release Lipopolysaccharide Pellets. *J Nutr*. 147(10), 1909–1916 (2017).
50. Zhao, L. et al. Gamma-tocotrienol attenuates high-fat diet-induced obesity and insulin resistance by inhibiting adipose inflammation and M1 macrophage recruitment. *Int J Obes (Lond)*. 39(3), 438–446 (2015).
51. Muto, C. et al. Gamma-tocotrienol reduces the triglyceride level in rat primary hepatocytes through regulation of fatty acid metabolism. *J Clin Biochem Nutr*. 52(1), 32–37 (2013).
52. Reagan-Shaw, S., Nihal, M. & Ahmad, N. Biological targets of tocotrienols for bone health: a translational approach. *Ann N Y Acad Sci*. 1401(1), 150–165 (2017).
53. Dufour, J. M. et al. Development of an ectopic site for islet transplantation using biodegradable scaffolds. *Tissue Engineering* 9/10, 1323–1331 (2005).
54. Bouxsein, M. L. et al. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. *J Bone Miner Res*. 25, 1468–1486 (2010).
55. Parfitt, A. M. et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. *J Bone Miner Res*. 2, 595–610 (1987).

Acknowledgements
This study was supported by American River Nutrition, Inc., Hadley, MA, and in part by the Obesity Research Cluster. JMD and GK were supported in part by The Ted Nash Long Life Foundation and The Jasper L and Jack Denton Wilson Foundation. We thank Jay Cao for bone analysis.

Author Contributions
C.L.S., G.K., D.W. and J.M.D. wrote the main manuscript text. M.D.T. conducted animal study. G.K., S.S., M.D.T., L.R. and E.C. collected data and perform laboratory work. C.L.S., G.K., L.R., E.C., N.M.M., H.M. and J.M.D. participated in study design. All authors reviewed the manuscript.

Additional Information
Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
